Ethicists Debate How to Tell Patients Secrets in their Genome
By Monya Baker,
Nature
| 11. 10. 2012
If parents have a son’s genes sequenced in hopes of explaining extreme muscle weakness, should they also be told whether he is likely to get Alzheimer’s disease as an adult? Should the child be told? When? How do answers to these questions shift for currently healthy adults? And should people be given more or less information depending on what they want to know?
As more and more people get large-scale sequencing as part of clinical care and research, the genetics community is struggling to define what to tell people about their own genomes. At the meeting of the American Society of Human Genetics, Holly Tabor at Seattle Children’s Hospital described an emerging approach to help people decide what results from their sequencing data they want to see and when.
Tabor has developed a web-based platform to manage the process. A website, called
my46, explains types of mutations and lets users select whether they want to get results about variants associated with drug response, disease risk, and ancestry. They can also select to find out whether they carry mutations for...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...